TEST:

OncoTarget® 500

OncoTarget® 500 integrates the robust bioinformatics of PGDx Elio Tissue Complete and provides physicians and researchers with medically actionable analyses on hundreds of cancer-related genes to help determine the specific genomic profile of an individual tumor. Based on the unique genomic profile of each patient's cancer, our test provides physicians with clinically actionable information to consider appropriate therapies for each patient and identify resistance to those therapies. OncoTarget®500 genomic profiling identifies tumor-based somatic mutations with high accuracy and sensitivity – single nucleotide variants (SNVs), small insertions and deletions, amplifications, translocations, microsatellite instability (MSI) and tumor mutation burden (TMB). OncoTarget® 500 is designed to be used by qualified healthcare professionals in accordance with professional guidelines in oncology for previously diagnosed cancer patients.